Keytruda's Urothelial Cancer Claim Goes From Accelerated To Full Approval, With More Limited Scope

 
• By Sue Sutter
Narrow opening
FDA has narrowed the first-line urothelial carcinoma population for Keytruda. • Source: Alamy

More from Approvals

More from Product Reviews